rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse

Biochemical and Biophysical Research Communications

Volumn 343, Issue 1, 2006, Pages 190-197

  Machida, Yoko ^a   Okada, Takashi ^b   Kurosawa, Masaru ^a   Oyama, Fumitaka ^a   Ozawa, Keiya ^b   Nukina, Nobuyuki ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Adeno associated virus; DARPP 32; Huntington disease; Polyglutamine; RNAi

Indexed keywords

HUNTINGTIN; PHOSPHOPROTEIN DARPP 32;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CORPUS STRIATUM; DOWN REGULATION; HUNTINGTON CHOREA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RNA INTERFERENCE; SYMPTOM; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOWN-REGULATION; GENE THERAPY; HUNTINGTON DISEASE; MICE; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; UP-REGULATION;

ADENO-ASSOCIATED VIRUS; ANIMALIA;

EID: 33645104092     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.02.141     Document Type: Article

References (33)

1. J.F. Gusella, and M.E. MacDonald Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease Nat. Rev. Neurosci. 1 2000 109 115
2. A.W. Dunah, H. Jeong, A. Griffin, Y.M. Kim, D.G. Standaert, S.M. Hersch, M.M. Mouradian, A.B. Young, N. Tanese, and D. Krainc Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease Science 296 2002 2238 2243
3. C.J. Cummings, M.A. Mancini, B. Antalffy, D.B. DeFranco, H.T. Orr, and H.Y. Zoghbi Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1 Nat. Genet. 19 1998 148 154
4. N.R. Jana, M. Tanaka, G. Wang, and N. Nukina Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity Hum. Mol. Genet. 9 2000 2009 2018
5. U. Nagaoka, K. Kim, N.R. Jana, H. Doi, M. Maruyama, K. Mitsui, F. Oyama, and N. Nukina Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions J. Neurochem. 91 2004 57 68
6. H. Doi, K. Mitsui, M. Kurosawa, Y. Machida, Y. Kuroiwa, and N. Nukina Identification of ubiquitin-interacting proteins in purified polyglutamine aggregates FEBS Lett. 571 2004 171 176
7. N.F. Bence, R.M. Sampat, and R.R. Kopito Impairment of the ubiquitin-proteasome system by protein aggregation Science 292 2001 1552 1555
8. A.V. Panov, C.A. Gutekunst, B.R. Leavitt, M.R. Hayden, J.R. Burke, W.J. Strittmatter, and J.T. Greenamyre Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines Nat. Neurosci. 5 2002 731 736
9. I. Sanchez, C. Mahlke, and J. Yuan Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders Nature 421 2003 373 379
10. M. Tanaka, Y. Machida, S. Niu, T. Ikeda, N.R. Jana, H. Doi, M. Kurosawa, M. Nekooki, and N. Nukina Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease Nat. Med. 10 2004 148 154
11. S.M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411 2001 494 498
12. J.Y. Yu, S.L. DeRuiter, and D.L. Turner RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells Proc. Natl. Acad. Sci. USA 99 2002 6047 6052
13. A.P. McCaffrey, and M.A. Kay A story of mice and men Gene Ther. 9 2002 1563
14. H. Hasuwa, K. Kaseda, T. Einarsdottir, and M. Okabe Small interfering RNA and gene silencing in transgenic mice and rats FEBS Lett. 532 2002 227 230
15. G.S. Ralph, P.A. Radcliffe, D.M. Day, J.M. Carthy, M.A. Leroux, D.C. Lee, L.F. Wong, L.G. Bilsland, L. Greensmith, S.M. Kingsman, K.A. Mitrophanous, N.D. Mazarakis, and M. Azzouz Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model Nat. Med. 11 2005 429 433
16. H. Xia, Q. Mao, S.L. Eliason, S.Q. Harper, I.H. Martins, H.T. Orr, H.L. Paulson, L. Yang, R.M. Kotin, and B.L. Davidson RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia Nat. Med. 10 2004 816 820
17. S.Q. Harper, P.D. Staber, X. He, S.L. Eliason, I.H. Martins, Q. Mao, L. Yang, R.M. Kotin, H.L. Paulson, and B.L. Davidson RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model Proc. Natl. Acad. Sci. USA 102 2005 5820 5825
18. E. Rodriguez-Lebron, E.M. Denovan-Wright, K. Nash, A.S. Lewin, and R.J. Mandel Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice Mol. Ther. 12 2005 618 633
19. Y.L. Wang, W. Liu, E. Wada, M. Murata, K. Wada, and I. Kanazawa Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA Neurosci. Res. 2005
20. A. Yamamoto, J.J. Lucas, and R. Hen Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease Cell 101 2000 57 66
21. S. Kotliarova, N.R. Jana, N. Sakamoto, M. Kurosawa, H. Miyazaki, M. Nekooki, H. Doi, Y. Machida, H.K. Wong, T. Suzuki, C. Uchikawa, Y. Kotliarov, K. Uchida, Y. Nagao, U. Nagaoka, A. Tamaoka, K. Oyanagi, F. Oyama, and N. Nukina Decreased expression of hypothalamic neuropeptides in Huntington disease transgenic mice with expanded polyglutamine-EGFP fluorescent aggregates J. Neurochem. 93 2005 641 653
22. R.E. Campbell, O. Tour, A.E. Palmer, P.A. Steinbach, G.S. Baird, D.A. Zacharias, and R.Y. Tsien A monomeric red fluorescent protein Proc. Natl. Acad. Sci. USA 99 2002 7877 7882
23. T. Okada, K. Shimazaki, T. Nomoto, T. Matsushita, H. Mizukami, M. Urabe, Y. Hanazono, A. Kume, K. Tobita, K. Ozawa, and N. Kawai Adeno-associated viral vector-mediated gene therapy of ischemia-induced neuronal death Methods Enzymol. 346 2002 378 393
24. T. Okada, T. Nomoto, T. Yoshioka, M. Nonaka-Sarukawa, T. Ito, T. Ogura, M. Iwata-Okada, R. Uchibori, K. Shimazaki, H. Mizukami, A. Kume, and K. Ozawa Large-scale production of recombinant viruses by use of a large culture vessel with active gassing Hum. Gene Ther. 16 2005 1212 1218
25. S.W. Davies, M. Turmaine, B.A. Cozens, M. DiFiglia, A.H. Sharp, C.A. Ross, E. Scherzinger, E.E. Wanker, L. Mangiarini, and G.P. Bates Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation Cell 90 1997 537 548
26. R. Luthi-Carter, A. Strand, N.L. Peters, S.M. Solano, Z.R. Hollingsworth, A.S. Menon, A.S. Frey, B.S. Spektor, E.B. Penney, G. Schilling, C.A. Ross, D.R. Borchelt, S.J. Tapscott, A.B. Young, J.H. Cha, and J.M. Olson Decreased expression of striatal signaling genes in a mouse model of Huntington's disease Hum. Mol. Genet. 9 2000 1259 1271
27. R.J. Ferrante, J.K. Kubilus, J. Lee, H. Ryu, A. Beesen, B. Zucker, K. Smith, N.W. Kowall, R.R. Ratan, R. Luthi-Carter, and S.M. Hersch Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice J. Neurosci. 23 2003 9418 9427
28. R.J. Ferrante, O.A. Andreassen, B.G. Jenkins, A. Dedeoglu, S. Kuemmerle, J.K. Kubilus, R. Kaddurah-Daouk, S.M. Hersch, and M.F. Beal Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease J. Neurosci. 20 2000 4389 4397
29. M. Chen, V.O. Ona, M. Li, R.J. Ferrante, K.B. Fink, S. Zhu, J. Bian, L. Guo, L.A. Farrell, S.M. Hersch, W. Hobbs, J.P. Vonsattel, J.H. Cha, and R.M. Friedlander Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease Nat. Med. 6 2000 797 801
30. M.V. Karpuj, M.W. Becher, J.E. Springer, D. Chabas, S. Youssef, R. Pedotti, D. Mitchell, and L. Steinman Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine Nat. Med. 8 2002 143 149
31. C. Burger, O.S. Gorbatyuk, M.J. Velardo, C.S. Peden, P. Williams, S. Zolotukhin, P.J. Reier, R.J. Mandel, and N. Muzyczka Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system Mol. Ther. 10 2004 302 317
32. M.Y. Mastakov, K. Baer, R.M. Kotin, and M.J. During Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: quantitative analysis of heparin co-infusion Mol. Ther. 5 2002 371 380
33. J.M. Van Raamsdonk, J. Pearson, D.A. Rogers, N. Bissada, A.W. Vogl, M.R. Hayden, and B.R. Leavitt Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease Hum. Mol. Genet. 14 2005 1379 1392